There is currently no evidence for a direct vaccine impact on the time to clear a pneumococcal colonisation episode, but it should be noted that the amount of data on this subject is very limited. Two studies have reported the vaccine effect on

future duration of colonisation and both found no effect of PCV [20] and [21]. In addition, the impact of PCV on existing colonisation seems limited [1]. An effect of PCV on the density of VT colonisation was shown in the American Indian trial in mTOR inhibitor review which those receiving PCV and nevertheless being colonised with the VT strains had lower density of colonisation as compared to those receiving the control vaccine and being colonised with the VT pneumococci [21]. Vaccine efficacy is generally defined as a relative reduction in some measure of risk in the vaccinated group compared to the unvaccinated group [15]. It is thus

expressed as 1-RR, where RR is the risk ratio. With colonisation as the event of interest, risk itself can be quantified concerning any of the endpoints discussed in Section 2. This means that there are several possible vaccine efficacy estimands (parameters) that could be considered even in the same study (Table 1). The two estimands of primary interest are VEacq, efficacy against pneumococcal acquisition, and VET, the combined efficacy against acquisition and duration of colonisation (Fig. 1). These two parameters bear immediate relevance to the direct and indirect BMN 673 manufacturer protection due to vaccination. The latter is a broader concept, Histone demethylase because it includes the potential vaccine effect on clearance of colonisation. Without assumptions of the vaccine effect on clearance, VET is the parameter that can be estimated in a cross-sectional study (Section 4). VEcol is an umbrella term including both VEacq and VET as well as other possible estimands of interest. Vaccine efficacy against acquisition, VEacq, is defined as the vaccine-induced relative

reduction in the hazard rate of acquisition of a select set of pneumococcal (vaccine) serotypes in the individual. The hazard relates to an individual susceptible to acquire the vaccine strains. Consequently, we define susceptibility as the state of being uncolonised by any of the vaccine types. It is also possible to consider VEacq in all subjects, irrespective of the current state of colonisation [10] and [11]. However, such unconditional VEacq does not take into account potential vaccine-induced within-host changes in the pneumococcal flora. Specifically, those already carrying vaccine serotypes then count as susceptible, and the unconditional vaccine efficacy is therefore smaller than VEacq conditioned on susceptibility.